Market Overview

Omeros Announces Additions to Senior Management Team

Share:

-- Hires Commercial and CMC Heads from Celgene --

Omeros Corporation (NASDAQ:OMER) today announced that it hired two new
senior management team members – Daniel Kirby as vice president and head
of commercial and Justin McCue, Ph.D. as vice president of chemistry,
manufacturing and controls (CMC). Their respective responsibilities
cover all of Omeros' programs, with the current primary areas of focus
for both being the continued expansion of market success for OMIDRIA®
(phenylephrine and ketorolac intraocular solution) 1% / 0.3% and
preparations for the commercialization of OMS721. OMIDRIA is the
company's marketed drug and the only product of its kind for cataract
and lens replacement surgery. OMS721 is Omeros' lead human monoclonal
antibody targeting mannan-binding lectin-associated serine protease-2
(MASP-2), the effector enzyme of the complement system's lectin pathway.
OMS721 is in Phase 3 clinical programs for hematopoietic stem
cell-associated thrombotic microangiopathy (HSCT-TMA), for
immunoglobulin A (IgA) nephropathy and for atypical hemolytic uremic
syndrome. OMS721 has been granted breakthrough therapy designations by
FDA for both HSCT-TMA and IgA nephropathy.

"I'm excited to be joining Omeros," said Daniel Kirby. "The breadth and
depth of the company's assets are truly impressive. With our marketed
drug OMIDRIA increasingly funding the pipeline, one of my primary
objectives is the rapid and successful commercialization of OMS721. With
multiple Phase 3 programs for OMS721 and strong clinical data across all
of the drug's current targeted indications, my team is focused on
expanding disease awareness and building market access, making OMS721
readily available for the benefit of patients and their treating
physicians."

"Omeros has strong and experienced leadership together with an
impressive and deep pipeline of both small-molecule and protein
therapeutic programs that holds multiple opportunities to develop new
and effective therapies," stated Justin McCue. "Using cutting-edge
science, development and manufacturing processes, the company is
advancing several candidate molecules with novel mechanisms of action,
all of which would likely be first-in-class. I look forward to helping
Omeros achieve its near-term goals of commercializing OMS721 and
successfully developing our diverse pipeline."

Mr. Kirby assumes the role of vice president and head of commercial at
Omeros, having joined the company from Celgene. At Celgene, he was the
U.S. commercial lead for its chimeric antigen receptor (CAR) T-cell
franchise. Before its acquisition by Celgene, Mr. Kirby built and led
the commercial marketing and market access functions in his role as vice
president and head of marketing/market access at Juno Therapeutics.
Prior to Juno, he was the head of marketing at Medivation where he
oversaw all of the marketing efforts for the blockbuster Xtandi®.
Mr. Kirby previously spent nearly 15 years in both marketing and sales
leadership roles at Amgen, including oversight of all U.S.
customer-facing marketing efforts for its multi-billion-dollar
granulocyte colony-stimulating factor (G-CSF) franchise NEULASTA®
and NEUPOGEN®. Before joining Amgen, he advanced through
commercial positions of increasing responsibility at GlaxoSmithKline.

As vice president of CMC, Dr. McCue oversees for Omeros all development,
manufacturing, and supply of both biological and small-molecule drugs.
Dr. McCue joins Omeros from Celgene where he headed the development of
CAR T-cell and T-cell receptor (TCR) therapy manufacturing processes.
Prior to Celgene, he led Biogen's CMC activities for the
multi-billion-dollar drugs AVONEX® and PLEGRIDY®,
approved for the treatment of multiple sclerosis in more than 90
countries. He began his career in the biopharmaceutical division at
Millipore. Dr. McCue earned his Ph.D. and completed a post-doctoral
fellowship in chemical engineering at Massachusetts Institute of
Technology (M.I.T.) after receiving a degree in chemical engineering at
University of California at Berkeley.

"Both Dan and Justin are strong and timely additions to our senior
leadership team, and we're pleased to have them on board," stated
Gregory A. Demopulos, M.D., chairman and chief executive officer of
Omeros. "Their successful track records in drug development and
commercialization speak for themselves. With OMIDRIA sales currently
tracking to challenge record quarterly revenues and OMS721 moving toward
commercialization, Dan and Justin's collective experience and expertise
are an excellent fit for our marketed, Phase 3 and pipeline programs.
Both have hit the ground running and, I look forward to each of them
contributing significantly to our success in bringing important new
drugs to patients worldwide."

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, complement-mediated diseases and disorders of the central
nervous system. The company's drug product OMIDRIA®
(phenylephrine and ketorolac intraocular solution) 1% / 0.3% is marketed
for use during cataract surgery or intraocular lens (IOL) replacement to
maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain. In the European
Union, the European Commission has approved OMIDRIA for use in cataract
surgery and other IOL replacement procedures to maintain mydriasis
(pupil dilation), prevent miosis (pupil constriction), and to reduce
postoperative eye pain. Omeros has multiple Phase 3 and Phase 2
clinical-stage development programs focused on: complement-associated
thrombotic microangiopathies; complement-mediated
glomerulonephropathies; cognitive impairment; and addictive and
compulsive disorders. In addition, Omeros has a diverse group of
preclinical programs and a proprietary G protein-coupled receptor (GPCR)
platform through which it controls 54 new GPCR drug targets and
corresponding compounds, a number of which are in preclinical
development. The company also exclusively possesses a novel
antibody-generating platform.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which are subject to the "safe
harbor" created by those sections for such statements. All statements
other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as "anticipate," "believe,"
"could," "estimate," "expect," "future", "goal," "intend," "likely",
"look forward to," "may," "on track", "plan," "potential," "predict,"
"project," "prospects," "should," "slated," "will," "would" and similar
expressions and variations thereof. Forward-looking statements are based
on management's beliefs and assumptions and on information available to
management only as of the date of this press release. Omeros' actual
results could differ materially from those anticipated in these
forward-looking statements for many reasons, including, without
limitation, risks associated with product commercialization and
commercial operations, unproven preclinical and clinical development
activities, regulatory oversight, intellectual property claims,
competitive developments, litigation, and the risks, uncertainties and
other factors described under the heading "Risk Factors" in the
company's Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 8, 2018. Given these risks,
uncertainties and other factors, you should not place undue reliance on
these forward-looking statements, and the company assumes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.

View Comments and Join the Discussion!